Industry Watching: Pharma and open data
June 24, 2008
GTO points to the announcement by GSK that it is making molecular profiling data from a number of cancer cell lines available via NCI’s caBIG. IMO, this is another example of pharma making data that on its own is not a competitive advantage available freely. In the next few years you will see pharma sponsored GWAS studies, molecular profiling data and safety markers being made available in some form of another. Hopefully not only will the data be made available, but it will be done in the public domain, so that others can take advantage of it, both for better science and for commercial purposes. There is only so much a single company can do or even look into.
Technorati Tags: GSK, caBIG, Open Data, Molecular Profiling
Posted by Deepak Singh | Filed Under Industry Watching, Open Science, Pharma, Trendspotting
Amazon Recommends
On FriendFeed, this post was liked by 1 person and commented on 0 times show
Add New Comment
Viewing 3 Comments
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Do you already have an account? Log in and claim this comment.
Do you already have an account? Log in and claim this comment.
Do you already have an account? Log in and claim this comment.
https://cabig.nci.nih.gov/tools/caArray_GSKdata
Add New Comment
Trackbacks